Stem Cell Agency Board Invests in Therapy Targeting Deadly Blood Cancers

Hematologic malignancies are cancers that affect the blood, bone marrow and lymph nodes and include different forms of leukemia and lymphoma. Current treatments can be effective, but in those patients that do not respond, there are few treatment options. Today, the governing Board of the California Institute for Regenerative Medicine (CIRM) approved investing $4.1 million in a therapy aimed at helping patients who have failed standard therapy. The CIRM Board also approved investing $44,101,935 in 11 projects as part of our Translational Research Program (TRAN). R. Hayes – Immusoft Corp. – Mucopolysaccharidosis type II: Plasma cell delivery of iduronate sulfatase – $3,994,676. Read more >>